UBQLN1 / Ubiquilin-1 · IHC design guide

Design Immunohistochemistry for UBQLN1

Plan UBQLN1 chromogenic IHC on paraffin sections using the documented formalin-fixed tissue example (datasheet: A00823 IHC-P). Compare cytoplasmic and nuclear staining across cell types, including low-staining hippocampal glia (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for UBQLN1 (IHC for UBQLN1): expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A00823, validated IHC image, and IHC protocol steps — Printable **UBQLN1** IHC protocol sheet — expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A00823, controls and protocol steps. Open the full UBQLN1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

UBQLN1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic and nuclear tissue staining (HPA tissue IHC)
	Staining pattern	Glandular and neuronal cells show cytoplasmic and nuclear staining (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Formalin-fixed paraffin sections were used (datasheet: A00823 IHC-P) (selected-SKU IHC image A00823)
	Caveat	Hippocampal glia show low staining (HPA tissue IHC)
	Regulation	No specific regulator reported (UniProt)
	Isoform / epitope	Four isoforms; shared epitope coverage is unverified (UniProt)

Section 1

Recommended UBQLN1 IHC & IF Protocols

Compare the catalog antibody’s datasheet IHC-P protocol with three published UBQLN1 IHC methods (PMC5779793; PMC8453688; PMC13094179).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	FFPE human cancer tissue (datasheet A00823)
Fixation	Image formalin-fixed; duration unreported (datasheet A00823); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-UBQLN1, 1:50-1:100 (datasheet A00823)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	UBQLN1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic and nuclear expression. No signal in the no-primary control.

💡Decision noteStart with Tris-EDTA pH 9.0 at 95–98 °C for 20 min (page retrieval rule); the published excerpts give no retrieval conditions.

Section 2

What Is the Expected UBQLN1 Staining Pattern?

UBQLN1 should show cytoplasmic and nuclear staining across multiple cell types in paraffin sections (HPA: general tissue IHC profile). HPA reports High staining in cerebral cortex neurons, colon glandular cells and several other sampled populations, with Supported tissue reliability and medium staining–RNA consistency (HPA: tissue IHC). UniProt also places UBQLN1 at the ER and in cytoplasmic vesicles; it has no transmembrane segment (UniProt Q9UMX0: location, topology).

What am I looking at on my slide?
Clear cytoplasmic and nuclear signal in cerebral cortex neurons or colon glandular cells (HPA: both High).	This fits the reported IHC compartment pattern and provides a useful positive reference (HPA: tissue IHC). Judge individual cells against adjacent tissue and the negative control; High is an HPA category, not a fixed staining threshold (HPA: tissue IHC; general IHC practice).
Predominantly sharp membrane-outline staining, without convincing cytoplasmic or nuclear signal.	Treat this as discordant with the general tissue IHC profile and examine specificity or staining artefact (HPA: cytoplasmic and nuclear profile; general IHC practice). UniProt lists cell-membrane association, but no transmembrane segment; that annotation alone does not establish a membrane-only paraffin-section pattern (UniProt Q9UMX0: location, topology).
Strong signal in hippocampal glia while expected positive cells stain weakly (HPA: glia Low).	Check antibody specificity and endogenous detection activity before interpreting the contrast biologically (general IHC practice). HPA calls hippocampal glial staining Low, not absent, and lists no negative tissue population; a positive glial cell is therefore not proof of cross-reactivity (HPA: tissue IHC).
Diffuse color over nuclei, cytoplasm and spaces between cells, with little cell-level definition.	This is poor evidence for UBQLN1 localization because the reported pattern is cellular (HPA: general cytoplasmic and nuclear expression). Compare the no-primary control, blocking and detection steps; diffuse deposit can arise from background detection or inadequate washing (general IHC practice).
No signal in a cerebral cortex or colon section expected to contain positive cells (HPA: High populations).	First suspect an assay or tissue-handling failure and check the run controls (general IHC practice). An absent result in one section cannot overturn HPA's observed population-level staining; its tissue reliability is Supported with medium staining–RNA consistency (HPA: tissue IHC).

💡Expected UBQLN1 appearanceA convincing positive is defined cytoplasmic and nuclear staining in an HPA High population, such as cerebral cortex neurons; widespread featureless color or isolated strong signal in a low-staining population calls for control review (HPA: tissue IHC; general IHC practice).

How each factor affects the staining
Choice of reference tissue	Cerebral cortex neurons, colon glandular cells and bone-marrow hematopoietic cells are HPA High examples (HPA: tissue IHC). HPA's list supplies useful positives, but its empty negative list does not identify a validated negative tissue (HPA: tissue IHC).
Cell compartment	General cytoplasmic and nuclear staining is the tissue-section expectation (HPA: tissue IHC). UniProt additionally annotates ER and autophagosomes; those locations do not require visibly distinct organelle patterns in chromogenic IHC (UniProt Q9UMX0: location; general IHC practice).
Isoforms and epitope	UniProt lists 4 UBQLN1 isoforms and a chain spanning residues 2–589 (UniProt Q9UMX0: isoforms, processing). The supplied record gives no antibody epitope, so these facts cannot predict which isoforms this stain detects.
Evidence behind antibody choice	CAB037256 is marked IHC Supported; HPA054143 has no IHC status in the supplied antibody list (HPA: antibody validation). Use the IHC-supported record as the relevant validation reference, while checking the actual reagent and controls used in the run (HPA: antibody validation; general IHC practice).
IF/ICC Q: Should fluorescence look identical?	A: HPA reports mainly nucleoplasmic signal with additional cytosol in ICC-IF, both Supported (HPA: subcellular ICC-IF). This informs compartment interpretation, but its cell-image result does not define chromogenic intensity in paraffin tissue (HPA: subcellular ICC-IF; general IHC practice).
Fixation and retrieval evidence	The supplied HPA and UniProt records do not report UBQLN1-specific fixation sensitivity or a retrieval condition. Assess retrieval through the assay's controls and reagent instructions, without inferring an effect from HPA staining levels or UniProt topology (general IHC practice).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Known-positive cells stain weakly or not at all (HPA: cerebral cortex neurons High).	Possible run failure, unsuitable retrieval, or detection setup (general IHC practice); UBQLN1-specific fixation sensitivity is unreported in the supplied sources.	Review section integrity, retrieval record, antibody use and detection controls; repeat alongside a known-positive section under the assay instructions (general IHC practice).
Color appears in the no-primary control.	The signal cannot be assigned to primary-antibody binding; endogenous enzyme activity or nonspecific detection is possible (general IHC practice).	Check the relevant endogenous-activity block and detection reagents, then compare the corrected control with the test section (general IHC practice).
Color blankets tissue and obscures cell boundaries.	Excess background can follow inadequate blocking, concentrated reagent or insufficient washing (general IHC practice).	Review blocking, working dilution and wash steps against the reagent instructions; seek defined cytoplasmic and nuclear cell staining (general IHC practice; HPA: tissue IHC profile).
Only nuclear or only cytoplasmic signal is visible.	The restricted pattern differs from HPA's general dual-compartment tissue profile, although individual cells may vary (HPA: tissue IHC).	Compare positive and no-primary controls and inspect several cell populations before assigning an abnormal localization (general IHC practice).
A membrane rim dominates the section.	The reported cell-membrane association does not itself establish a membrane-only IHC result (UniProt Q9UMX0: location, topology).	Check for concurrent cytoplasmic and nuclear staining, inspect morphology and controls, and avoid calling the rim specific from topology alone (HPA: tissue IHC; general IHC practice).
A low-staining population appears stronger than the positive reference (HPA: hippocampal glia Low).	Biological variation, background or cross-reactivity remain possibilities; HPA's Low category does not mean negative (HPA: tissue IHC; general IHC practice).	Recheck cell identification, the positive reference and negative control; interpret the contrast only after the controls support specific staining (general IHC practice).

Source: UniProt Q9UMX0 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing UBQLN1 staining

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

A00823 · IHCFormalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary

Immunofluorescent analysis of Hela cells, using Ubiquilin1 Antibody (Center) . A00823 was diluted at 1:100 dilution. Alexa Fluor 488-conjugated goat anti-rabbit lgG at 1:400 dilution was used as the secondary antibody (green). Cytoplasmic actin was counterstained with Dylight Fluor® 554 (red) conjugated Phalloidin (red).

A00823 · IFImmunofluorescent analysis of Hela cells, using Ubiquilin1 Antibody (Center) . A00823 was diluted at 1:100 dilution. Alexa Fluor 488-conjuga

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000135018-UBQLN1/tissue/cerebral+cortex#imid_8688124

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000135018-UBQLN1/tissue/colon#imid_8686394

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000135018-UBQLN1/tissue/liver#imid_8686387

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000135018-UBQLN1/tissue/kidney#imid_8686388

HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA054143; green = UBQLN1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for UBQLN1 IHC & IF

🧪Run caudate first and score neuronal cells, which HPA rates High for UBQLN1 (HPA: caudate neuronal cells, High). HPA detects UBQLN1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and treat cells without visible chromogen on the positive slide as unstained cells rather than validated biological negatives (HPA: no negative tissue rows; detected in all 45 scored tissues).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: None in HPA: UBQLN1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show UBQLN1 in U-251MG, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only slide and an isotype control matched to the primary antibody’s host species and clonality; a confirmed UBQLN1 knockout provides a biological negative (standard IHC practice). Block endogenous peroxidase for chromogenic detection, and check caudate sections for pigment that could be mistaken for staining (standard IHC practice).

⚠️Feasibility: The selected A00823 caption explicitly reports formalin-fixed, paraffin-embedded tissue with peroxidase/AEC detection, but supplies no target-specific fixation window or fixation effect (selected A00823 tissue-IHC caption). Retrieval conditions and their effect on UBQLN1 staining are unreported in the supplied evidence (selected A00823 tissue-IHC caption). ICC-IF images exist for U-251MG and U2OS, with supported nucleoplasmic and additional cytosolic localization; no supplied frozen-section evidence establishes whether frozen IHC or IF is easier than paraffin IHC (HPA: subcellular ICC-IF).

HPA tissue IHC evidence for UBQLN1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Appendix	Lymphoid tissue	High	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Caudate	Neuronal cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: UBQLN1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced UBQLN1 IHC Tips

Troubleshoot UBQLN1 staining in paraffin sections by checking retrieval, compartment patterns, controls, and scoring before interpreting changes in signal.

How should I adjust retrieval when UBQLN1 staining is weak or uneven?

Use Tris-EDTA pH 9.0 heat-induced epitope retrieval at 95–98 °C for 20 min for UBQLN1 IHC-P (page retrieval setting). Keep section thickness, heating time, cooling, and detection conditions consistent while comparing runs, because these variables affect staining intensity (standard IHC practice). If staining remains weak, test citrate buffer pH 6.0 on adjacent sections as a fallback, with a known positive control and matched exposure to chromogen (standard IHC practice). Assess both cytoplasmic and nuclear staining, since the supported tissue profile includes both compartments, and reject conditions that increase diffuse background or tissue damage (HPA tissue IHC; standard IHC practice).

Could fixation explain inconsistent UBQLN1 staining across paraffin blocks?

UBQLN1-specific sensitivity to fixation duration or fixative chemistry is unknown from the supplied evidence; do not infer it from tissue staining patterns or protein features (evidence scope). For a comparison, process matched sections with the same fixation history where possible, then hold the pH 9.0, 20 min retrieval and detection conditions constant (page retrieval setting; standard IHC practice). Record fixative, time to fixation, and fixation duration for each block, because preanalytic differences can change epitope accessibility and tissue preservation (standard IHC practice). If blocks differ, compare staining within similarly processed groups and check a positive control in each run before attributing intensity differences to UBQLN1 abundance (standard IHC practice).

Which UBQLN1 staining compartments should I accept in tissue sections?

Expect a mixture of cytoplasmic and nuclear signal in tissue sections, rather than requiring a single compartment (HPA tissue IHC). A supported subcellular profile places UBQLN1 mainly in nucleoplasm with additional cytosol staining, while UniProt also lists ER, autophagosomes, and cell membrane (HPA subcellular; UniProt Q9UMX0 subcellular). UBQLN1 has no transmembrane segment, so a crisp membrane-only outline should prompt review of controls and morphology before interpretation (UniProt Q9UMX0 topology; standard IHC practice). Compare cells within the same section at identical chromogen development and counterstain settings, and document nuclear and cytoplasmic intensity separately when patterns differ (standard IHC practice).

How can isoforms or epitope placement complicate UBQLN1 IHC interpretation?

UBQLN1 has 4 annotated isoforms, but the supplied product evidence does not identify this antibody’s epitope or establish which isoforms it detects (UniProt Q9UMX0 isoforms; evidence scope). Its ubiquitin-like region spans residues 37–111 and its UBA region spans 546–586; domain location alone cannot establish antibody specificity (UniProt Q9UMX0 domains; standard IHC practice). Request the immunogen or epitope information for the exact catalog antibody before claiming isoform-specific staining, and compare with orthogonal expression evidence where available (standard IHC practice). If staining differs between compartments, score those patterns separately rather than assigning an isoform from chromogenic morphology alone (HPA tissue IHC; standard IHC practice).

How should I adapt UBQLN1 assessment for a separate IF multiplex experiment?

For IF, pair UBQLN1 with a marker identifying the expected cell population, then inspect nuclear and cytosolic signal in individual cells (HPA subcellular; standard IF practice). Choose spectrally separated fluorophores and place a brighter, longer-wavelength label on the weaker target channel when tissue autofluorescence is troublesome; include single-label controls (standard IF practice). Because UBQLN1 is reported in nucleoplasm and cytosol and has no transmembrane segment, permeabilise for intracellular access, then optimise detergent strength against morphology and background (HPA subcellular; UniProt Q9UMX0 topology; standard IF practice). IF images are listed for U-251MG and U2OS, but the IHC tissue caption does not establish IF fixation or permeabilisation conditions for this antibody (HPA subcellular; A00823 tissue-IHC caption).

What should I check when UBQLN1 chromogen appears across most of the section?

UBQLN1 is described as ubiquitous, and the tissue IHC profile reports general cytoplasmic and nuclear expression, so widespread staining can be plausible but still needs controls (UniProt Q9UMX0 tissue specificity; HPA tissue IHC). Inspect a no-primary control for secondary-reagent signal, and block endogenous peroxidase before chromogenic detection when using a peroxidase workflow (standard IHC practice). Reduce primary concentration through a documented titration, optimise blocking and washes, and compare each adjustment on adjacent sections with identical chromogen development (standard IHC practice). Separate diffuse haze from cell-shaped nuclear or cytoplasmic staining, and exclude tissue edges, folds, and necrotic areas when judging background (HPA tissue IHC; standard IHC practice).

How should I score UBQLN1 when both nuclear and cytoplasmic signals vary? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and region of interest before scoring, then record nuclear and cytoplasmic staining separately because both patterns occur in tissue IHC (HPA tissue IHC; standard IHC practice). An H-score can combine the percentage of cells at intensity grades 0–3; also report the percentage positive at a prespecified threshold (standard IHC practice). For spatial comparisons, report positive-cell density per mm² of viable tissue, or normalise positive cells to the total eligible cells in the same compartment (standard IHC practice). Keep retrieval, chromogen development, counterstain, imaging, and threshold settings consistent, and exclude folds and necrosis from measured areas (standard IHC practice).

How do I distinguish credible UBQLN1 staining from artefact or overinterpretation?

Credible UBQLN1 staining should have interpretable cell morphology and nuclear or cytoplasmic localisation consistent with the supported tissue profile (HPA tissue IHC; standard IHC practice). Check cell identity against the section: HPA reports high staining in several populations, including neuronal cells in caudate and cerebral cortex, while hippocampal glial cells are listed as low (HPA tissue IHC). Treat isolated edge staining, necrotic deposits, and signal persisting in a no-primary control as possible artefacts; investigate endogenous enzyme activity in peroxidase detection (standard IHC practice). The A00823 image documents formalin-fixed, paraffin-embedded human cancer tissue with peroxidase and AEC staining, but its caption does not establish clinical relevance (A00823 tissue-IHC caption).

Boster reagents

Best UBQLN1 / Ubiquilin-1 IHC Antibodies

A00823 has human formalin-fixed, paraffin-embedded tissue IHC data (IHC image caption) and HeLa cell IF data (IF image caption); the catalog also lists mouse reactivity (catalog: reactivity).

Real IHC data Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Anti-Ubiquilin1 Antibody (Center)

Cat # A00823

View product →

A00823 will render with IHC data from human breast carcinoma and hepatocarcinoma tissue (IHC image caption: BC and HC). Its listed applications include IHC-P and IF (catalog: applications), with IF data from HeLa cells (IF image caption) and stated human and mouse reactivity (catalog: reactivity).

Which to pick: Choose A00823 for formalin-fixed, paraffin-embedded human tissue IHC because its own image caption documents that preparation (IHC image caption). Choose A00823 for cell IF because its own image caption documents HeLa staining (IF image caption). For human and mouse samples, A00823 is the listed polyclonal option (catalog: dilution_raw and reactivity); the supplied images document human samples only (IHC and IF image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9UMX0 (UBQL1_HUMAN, Ubiquilin-1).
Human Protein Atlas. UBQLN1 tissue IHC expression (reliability: Supported).
Human Protein Atlas. UBQLN1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
Human Protein Atlas. UBQLN1 antibody validation summary (2 antibodies).
Clinical significance of ubiquilin 1 in gastric cancer. Medicine 2018 — PMC5779793.
Abnormally elevated ubiquilin‑1 expression in breast cancer regulates metastasis and stemness via AKT signaling. Oncology reports 2021 — PMC8453688.
UBQLN1 Inhibition reduces MASH progression through downregulating SIKE/p38 MAPK pathway in hepatocyte. Journal of nanobiotechnology 2026 — PMC13094179.
UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal transduction and targeted therapy 2021 — PMC8129126.
PubMed PMID:11076969 — UniProt-cited evidence.
PubMed PMID:10983987 — UniProt-cited evidence.
PubMed PMID:10807547 — UniProt-cited evidence.